Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris

Abstract

Psoriasis is one of the most common skin diseases. The mainstay of treatment for the vast majority of patients is topical therapy. A rising first-line treatment modality for psoriasis vulgaris is the two-compound ointment containing calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g (Dovobet^®, Daivobet^®, Taclonex^®), which combines a vitamin D analog and a corticosteroid. This innovative formulation preserves the activity and bioavailability of the two components and many clinical studies have demonstrated that it has a greater efficacy, tolerability, and a rapid onset of action compared with its individual ingredients or tacalcitol.

Keywords:

• psoriasis
• calcipotriol/betamethasone dipropionate
• dovobet
• daivobet
• taclonex